

## Press Release

February 3, 2008

### **TEGO® Pep 4-17: Collagen boosting bioactive for anti-aging formulations**

**Dr. Hans Kreul**  
Evonik Goldschmidt GmbH  
Public Relations  
Phone +49 201 173-2415  
Fax +49 201 173-1838  
hans.kreul@degussa.com

The business line Personal Care of Evonik has launched TEGO® Pep 4-17, a novel bioactive and pure tetrapeptide with outstanding anti-aging properties for skin care formulations. It activates collagen production and therefore stimulates dermal filling, repair, and renewal mechanisms of the skin.

Tetrapeptide-17 is based on skins own structures. Formulations with TEGO® Pep 4-17 lead to an increased elasticity, a decreased volume of wrinkles and fine lines as well as a reduction of skin roughness. The recommended usage level is 0.5 - 5.0 per cent.

The product is identified by an in-silico (bioinformatic) approach of prediction of biologically active ECM breakdown products.

#### **Company information**

Evonik Industries is the creative industrial group from Germany which operates in three business areas: Chemicals, Energy and Real Estate. Evonik is a global leader in specialty chemicals, an expert in power generation from hard coal and renewable energies, and one of the largest private residential real estate companies in Germany. Our strengths are creativity, specialization, continuous self-renewal, and reliability. Evonik is active in over 100 countries around the world. In its fiscal year 2007 about 43,000 employees generated sales of about €14.4 billion and an operating profit (EBIT) of more than €1.3 billion (preliminary figures).

#### **Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.